BioXcel Therapeutics Inc
(FRA:BX2)
€
0.5724
0.0254 (4.64%)
Market Cap: 25.17 Mil
Enterprise Value: 68.70 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 18/100 BioXcel Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 11, 2021 / 12:45PM GMT
Release Date Price:
€24.49
(-2.04%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Okay. Good morning. Welcome to the first day of the Virtual Vegas Bank of America Health Care Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here, and I have Gregory Harrison for my team. And we're thrilled to have for a fireside chat, BioXcel Therapeutics. And sitting with us today, we have CEO, Vimal Mehta; we also have Chief Commercial Officer, William Kane. Guys, good morning.
Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, & Director
Good morning.
William P. Kane
BioXcel Therapeutics, Inc. - Executive VP & Chief Commercial Officer
Good morning.
Questions & Answers
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
So well, Greg and I, will ask some questions here, but I guess I'll kick it off with kind of the bigger picture for either Will or Vimal. Just to talk about the 501 launch.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot